Dendritic spine dysgenesis in autism related disorders

Neuroscience Letters

Volumn 601, Issue , 2014, Pages 30-40

  Phillips, Mary ^a   Pozzo Miller, Lucas ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Fragile X; Intellectual disability; MeCP2; MGluR; MTOR; Rett syndrome; TrkB

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

AUTISM; BEHAVIOR DISORDER; BONE STRUCTURE; BRAIN DEVELOPMENT; DENDRITIC SPINE; DENDRITIC SPINE DYSGENESIS; DOWN SYNDROME; FRAGILE X SYNDROME; GENE MUTATION; HAPPY PUPPET SYNDROME; HUMAN; MEDICAL HISTORY; NERVE CELL PLASTICITY; NERVOUS SYSTEM FUNCTION; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RETT SYNDROME; REVIEW; SIGNAL TRANSDUCTION; SPINE MALFORMATION; SYNAPTIC MEMBRANE; TUBEROUS SCLEROSIS; ANIMAL; COMPLICATION; INTELLECTUAL IMPAIRMENT; PATHOLOGY; PHYSIOLOGY;

ANGELMAN SYNDROME; ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DENDRITIC SPINES; DOWN SYNDROME; FRAGILE X SYNDROME; HUMANS; INTELLECTUAL DISABILITY; RETT SYNDROME; TUBEROUS SCLEROSIS;

EID: 84952628323     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.01.011     Document Type: Review

References (233)

1. Ramon y S., Cajal Estructura de los centros nerviosos de las aves. Rev. Tri. Hist. Norm. Pat. 1888, 1:1-10. http://www.the-scientist.com/?articles.view/articleNo/37954/title/The-Neuron-Doctrine-circa-1894/.
2. Ramón y Cajal S. Significación fisiológica de las expansiones protoplásmicas y nerviosas de la sustancia gris. Rev. Cienc. Med. Barc. 1891, 22:23.
3. Ramón y Cajal S. La fine structure des centres nerveaux the Croonian Lecture. Proc. R. Soc. London 1894, 55:443-468.
4. Sherrington C.S., Laslett E.E. Observations on some spinal reflexes and the interconnection of spinal segments. J. Physiol. 1903, 29:58-96. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1540608&tool=pmcentrez&rendertype=abstract.
5. Bhatt D.H., Zhang S., Gan W.-B. Dendritic spine dynamics. Annu. Rev. Physiol. 2009, 71:261-282. 10.1146/annurev.physiol.010908.163140.
6. Yuste R., Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Ann. Rev. Neurosci. 2001, 24:1071-1089.
7. Dierssen M., Ramakers G.J.A. Dendritic pathology in mental retardation: from molecular genetics to neurobiology. Genes Brain Behav. 2006, 5(Suppl. 2):48-60. 10.1111/j.1601-183X.2006.00224.x.
8. Kaufmann W.E., Moser H.W. Dendritic anomalies in disorders associated with mental retardation. Cereb. Cortex 2000, 10:981-991. http://www.ncbi.nlm.nih.gov/pubmed/11007549.
9. Penzes P., Cahill M.E., a Jones K., VanLeeuwen J.-E., Woolfrey K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci. 2011, 14:285-293. 10.1038/nn.2741.
10. Purpura D.P. Spine dysgenesis and mental retardation. Science 1974, 80(186):1126-1128.
11. Ziv N.E., Smith S.J. Evidence for a role of dendritic filopodia in synaptogenesis and spine formation. Neuron 1996, 17:91-102. 10.1016/S0896-6273(00)80283-4.
12. Dailey M.E., Smith S.J. The dynamics of dendritic structure in developing hippocampal slices. J. Neurosci. 1996, 76:2983-2994.
13. Fiala J.C., Feinberg M., Popov V., Harris K.M. Synaptogenesis Via Dendritic Filopodia in Developing Hippocampal Area CA1. J. Neurosci. 1998, 18:8900-8911. http://www.jneurosci.org/content/18/21/8900long.
14. Zuo Y., Lin A., Chang P., Gan W.-B. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron 2005, 46:181-189. 10.1016/j.neuron.2005.04.001.
15. De Felipe J., Marco P., a Fairén, Jones E.G. Inhibitory synaptogenesis in mouse somatosensory cortex. Cereb. Cortex 1997, 7:619-634. http://www.ncbi.nlm.nih.gov/pubmed/9373018.
16. Huttenlocher P.R. Morphometric study of human cerebral cortex development. Neuropsychologia 1990, 28:517-527. 10.1016/0028-3932(90)90031-I.
17. Peters A., Kaiserman-Abramof I.R. The small pyramidal neuron of the rat cerebral cortex, the perikaryon, dendrites and spines. Am. J. Anat. 1970, 127:321-355. 10.1002/aja.1001270402.
18. Matsuzaki M., Ellis-Davies G.C.R., Nemoto T., Miyashita Y., Iino M., Kasai H. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat. Neurosci. 2001, 4:1086-1092. 10.1038/nn736.
19. Holtmaat A.J.G.D., Trachtenberg J.T., Wilbrecht L., Shepherd G.M., Zhang X., Knott G.W., et al. Transient and persistent dendritic spines in the neocortex in vivo. Neuron 2005, 45:279-291. 10.1016/j.neuron.2005.01.003.
20. Korkotian E., Holcman D., Segal M. Dynamic regulation of spine-dendrite coupling in cultured hippocampal neurons. Eur. J. Neurosci. 2004, 20:2649-2663. 10.1111/j.1460-9568.2004.03691.x.
21. 2+ signaling in dendrites. Neuron 2005, 46:609-622. 10.1016/j.neuron.2005.03.015Spine-Neck.
22. Takumi Y., Ramírez-León V., Laake P., Rinvik E., Ottersen O.P. Different modes of expression of AMPA and NMDA receptors in hippocampal synapses. Nat. Neurosci. 1999, 2:618-624. 10.1038/10172.
23. Levenga J., Willemsen R. Perturbation of dendritic protrusions in intellectual disability. Prog. Brain Res. 2012, 197:153-168. 10.1016/B978-0-444-54299-1.00008-X.
24. Lee K.F.H., Soares C., Béïque J.-C. Examining form and function of dendritic spines. Neural Plast. 2012, 2012:1-9. 10.1155/2012/704103.
25. Van Harreveld A., Fifkova E. Swelling of dendritic spines in the fascia dentata after stimulation of the perforant fibers as a mechanism of post-tetanic potentiation. Exp. Neurol. 1975, 49:736-749. 10.1016/0014-886(75)90,055-2.
26. Fifková E., Van Harreveld A. Long-lasting morphological changes in dendritic spines of dentate granular cells following stimulation of the entorhinal area. J. Neurocytol. 1977, 6:211-230. 10.1007/BF01261506.
27. Park M., Salgado J.M., Ostroff L., Helton T.D., Robinson C.G., Harris K.M., et al. Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes. Neuron 2006, 52:817-830. 10.1016/j.neuron.2006.09.040.
28. Noguchi J., Nagaoka A., Watanabe S., Ellis-Davies G.C.R., Kitamura K., Kano M., et al. In vivo two-photon uncaging of glutamate revealing the structure-function relationships of dendritic spines in the neocortex of adult mice. J. Physiol. 2011, 589:2447-2457. 10.1113/jphysiol.2011.207100.
29. Fifková E., Anderson C.L. Stimulation-induced changes in dimensions of stalks of dendritic spines in the dentate molecular layer. Exp. Neurol. 1981, 74:621-627. 10.1016/0014-4886(81)90197-7.
30. Okamoto K.-I., Nagai T., Miyawaki A., Hayashi Y. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. Nat. Neurosci. 2004, 7:1104-1112. 10.1038/nn1311.
31. Zhou Q., Homma K.J., Poo M. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004, 44:749-757. 10.1016/j.neuron.2004.11.011.
32. Matsuzaki M., Honkura N., Ellis-Davies G.C.R., Kasai H. Structural basis of long-term potentiation in single dendritic spines. Nature 2004, 429:761-766. 10.1038/nature02617.
33. Trachtenberg J.T., Chen B.E., Knott G.W., Feng G., Sanes J.R., Welker E., et al. Long-term in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 2002, 420:788-794. 10.1038/nature01273.
34. Grutzendler J., Kasthuri N., Gan W.-B. Long-term dendritic spine stability in the adult cortex. Nature 2002, 420:812-816. 10.1038/nature01276.
35. Grunditz A., Holbro N., Tian L., Zuo T.G. Spine neck plasticity controls postsynaptic calcium signals through electrical compartmentalization. J. Neurosci. 2008, 28:13457-13466. 10.1523/JNEUROSCI.2702-08.2008.
36. Bloodgood B.L., Sabatini B.L. Neuronal activity regulates diffusion across the neck of dendritic spines. Science 2005, 310:866-869. 10.1126/science.1114816.
37. Kasai H., Matsuzaki M., Noguchi J., Yasumatsu N., Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci. 2003, 26:360-368. 10.1016/S0166-2236(03)00162-0.
38. Ghaziuddin M., Tsai L., Ghaziuddin N. Autism in Down's syndrome: presentation and diagnosis. J. Intellect. Disabil. Res. 1992, 36:449-456.
39. Kent L., Evans J., Paul M., Sharp M. Comorbidity of autistic spectrum disorders in children with down syndrome. Dev. Med. Child Neurol. 1999, 41:153-158. http://www.ncbi.nlm.nih.gov/pubmed/10210247.
40. York A., von Fraunhofer N., Turk J., Sedgwick P. Fragile-X syndrome, Down's syndrome and autism: awareness and knowledge amongst special educators. J. Intellect. Disabil. Res. 1999, 43:314-324. 10.1046/j. 1365-2788.1999.00219.x.
41. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 2004, 5:725-738. 10.1038/nrg1448.
42. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J. Comp. Neurol. 1976, 167:63-81. 10.1002/cne.901670105.
43. Suetsugu M., Mehraein P. Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome. Acta Neuropathol. 1980, 50:207-210. 10.1007/BF00688755.
44. Takashima S., Becker L.E., Armstrong D.L., Chan F. Abnormal neuronal development in the visual cortex of the human fetus and infant with Down's syndrome. A quantitative and qualitative golgi study. Brain Res. 1981, 225:1-21. 10.1016/0006-8993(81) 90,314-0.
45. Ferrer I., Gullotta F. Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta Neuropathol. 1990, 79:680-685. 10.1007/BF00294247.
46. Takashima S., Iida K., Mito T., Arima M. Dendritic and histochemical development and ageing in patients with Down's syndrome. J. Intellectual Disabil. Res. 1994, 38.
47. Takashima A., Ieshima H. Dendrites, dementia and the Down syndrome. Brain Dev. 1989, 11:131-133. 10.1016/S0387-7604(89)80082-8.
48. Benavides-Piccione R., Ballesteros-Yáñez I., de Lagrán M.M., Elston G., Estivill X., Fillat C., et al. On dendrites in Down syndrome and DS murine models: a spiny way to learn. Prog. Neurobiol. 2004, 74:111-126. 10.1016/j.pneurobio.2004.08.001.
49. Liu C., Belichenko P.V., Zhang L., Fu D., Kleschevnikov A.M., Baldini A., et al. Mouse models for Down syndrome-associated developmental cognitive disabilities. Dev. Neurosci. 2011, 33:404-413. 10.1159/000329422.
50. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. 1990, 360:263-280. http://europepmc.org/abstract/MED/2147289.
51. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., et al. A mouse model for Down syndrome exhbits learning and behavior deficits. Nat. Genet. 1995, 11:177-184.
52. Kleschevnikov A.M., Belichenko P., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 2004, 24:8153-8160. 10.1523/JNEUROSCI 1766-04.2004.
53. Belichenko P.V., Kleschevnikov A.M., Salehi A., Epstein C.J., Mobley W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J. Comp. Neurol. 2007, 504:329-345. 10.1002/cne.21433.
54. Belichenko N.P., Belichenko P.V., Kleschevnikov A.M., Salehi A., Reeves R.H., Mobley W.C. The Down syndrome critical region is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 2009, 29:5938-5948. 10.1523/JNEUROSCI 154-709.2009.
55. Popov V.I., Kleschevnikov A.M., Klimenko O.A., Stewart M.G., Belichenko P.V. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2011, 519:1338-1354. 10.1002/cne.22573.
56. Siarey R.J., Carlson E.J., Epstein C.J., a Balbo S.I., Rapoport, Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920. http://www.ncbi.nlm.nih.gov/pubmed/10608287.
57. Scott-McKean J.J., Costa A.C.S. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn. Memory 2011, 18:774-778. 10.1101/lm.024182.111.
58. Davies K.J.A., Ermak G., Rothermel B.A., Pritchard M., Heitman J., Ahnn J., et al. Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. FASEB J. 2007, 21:3023-3028. 10.1096/fj.06-7246com.
59. Thomazeau A., Lassalle O., Iafrati J., Souchet B., Guedj F., Janel N., et al. Prefrontal deficits in a murine model overexpressing the Down syndrome candidate gene dyrk1a. J. Neurosci. 2014, 34:1138-1147. 10.1523/JNEUROSCI.2852-13.2014.
60. Hoeffer C.A., Dey A., Sachan N., Wong H., Patterson R.J., Shelton J.M. The Down syndrome critical region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. J. Neurosci. 2007, 27:13161-13172. 10.1523/JNEUROSCI.3974-07.2007.
61. Dierssen M., Arqué G., McDonald J., Andreu N., Martínez-Cué C., Flórez J., et al. Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1. PLoS One 2011, 6:e17010. 10.1371/journal.pone.0017010.
62. Martin K.R., Corlett A., Dubach D., Mustafa T., Coleman H.A., Parkington H.C., et al. Over-expression of RCAN1 causes Down syndrome-like hippocampal deficits that alter learning and memory. Hum. Mol. Genet. 2012, 21:3025-3041. 10.1093/hmg/dds134.
63. Wang W., Zhu J.Z., Chang K.T., Min K.-T. DSCR1 interacts with FMRP and is required for spine morphogenesis and local protein synthesis. EMBO J. 2012, 31:3655-3666. 10.1038/emboj.2012.190.
64. Chang K.T., Ro H., Wang W., Min K.-T. Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome. Trends Neurosci. 2013, 36:685-694. 10.1016/j.tins.2013.08.007.Meeting.
65. Weiler I.J., Irwin S.A., Klintsova A.Y., Spencer C.M., Brazelton A.D., Miyashiro K., et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. 1997, 94:5395-5400. 10.1073/pnas.94.10.5395.
66. Irwin S.A., Galvez R., Greenough W.T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 2000, 10:1038-1044. 10.1093/cercor/10.10.1038.
67. Waung M.W., Huber K.M. Protein translation in synaptic plasticity: mGluR-LTD, Fragile X. Curr. Opin. Neurobiol. 2009, 19:319-326. 10.1016/j.conb.2009.03.011.
68. Bagni C., Greenough W.T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat. Rev. Neurosci. 2005, 6:376-387. 10.1038/nrn1667.
69. Bassell G.J., Warren S.T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201-214. 10.1016/j.neuron.2008.10.004.
70. Clayton-Smith J. Angelman syndrome: a review of the clinical and genetic aspects. J. Med. Genet. 2003, 40:87-95. 10.1136/jmg.40.2.87.
71. Kaplan L.C., Wharton R., Elias E., Mandell F., Donlon T., Latt S.A. Clinical heterogeneity associated with deletions in the long arm of chromosome 15: report of 3 new cases and their possible genetic significance. Am. J. Med. Genet. 1987, 28:45-53. 10.1002/ajmg.1320280107.
72. Williams C.A., Driscoll D.J., Dagli A.I. Clinical and genetic aspects of Angelman syndrome. Genet. Med. 2010, 12:385-395. 10.1097/GIM.0b013e3181def138.
73. Albrecht U., Sutcliffe J.S., Cattanach B.M., Beechey C., Armstrong D., Eichele G. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat. Genetics 1997, 17:75-78. 10.1038/ng0997-75.
74. Jiang Y.-H., Tsai T.-F., Bressler J., Beaudet A.L. Imprinting in Angelman and Prader-Willi syndromes. Curr. Opin. Genet. Dev. 1998, 8:334-342. 10.1016/S0959-437X(98)80091-9.
75. Rougeulle C., Cardoso C., Fontés M., Colleaux L., Lalande M. An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. Nat. Genet. 1998, 19:15-16. 10.1038/ng0598-15.
76. Runte M., Huttenhofer A., Gross S., Kiefmann M., Horsthemke B., Buiting K. The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar RNA species and as an antisense RNA for UBE3A. Hum. Mol. Genet. 2001, 10:2687-2700. 10.1093/hmg/10.23.2687.
77. Yamasaki K. Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum. Mol. Genet. 2003, 12:837-847. 10.1093/hmg/ddg106.
78. Runte M., Kroisel P.M., Gillessen-Kaesbach G., Varon R., Horn D., Cohen M.Y., et al. SNURF-SNRPN and UBE3A transcript levels in patients with Angelman syndrome. Hum. Genet. 2004, 114:553-561. 10.1007/s00439-004-1104-z.
79. Landers M., Bancescu D.L., Le Meur E., Rougeulle C., Glatt-Deeley H., Brannan C., et al. Regulation of the large (approximately 1000) imprinted murine Ube3a antisense transcript by alternative exons upstream of Snurf/Snrpn. Nucleic Acids Res. 2004, 32:3480-3492. 10.1093/nar/gkh670.
80. Browne C.E., Dennis N.R., Maher E., Long F.L., Nicholson J.C., Sillibourne J., et al. Inherited interstitial duplications of proximal 15q: genotype-phenotype correlations. Am. J. Hum. Genet. 1997, 61:1342-1352. 10.1086/301624.
81. Cook E.H., Lindgren V., Leventhal B.L., Courchesne R., Lincoln A., Shulman C. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am. J. Hum. Genet. 1997, 60:928-934. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1712464&tool=pmcentrez&rendertype=abstract.
82. Mao R., Jalal S.M., Snow K., Michels V.V., Szabo S.M., Babovic-Vuksanovic D. Characteristics of two cases with dup(15) (q 11.2-q 12): one of maternal and one of paternal origin. Genet. Med. 2000, 2:131-135. 10.1097/00125817-200003000-00003.
83. Dykens E.M., Lee E., Roof E. Prader-Willi syndrome and autism spectrum disorders: an evolving story. J. Neurodev. Disord. 2011, 3:225-237. 10.1007/s11689-011-9092-5.
84. Trillingsgaard A., ØStergaard J.R. Autism in Angelman syndrome: an exploration of comorbidity. Autism 2004, 8:163-174. 10.1177/1362361304042720.
85. Jiang Y.-H., Armstrong D., Albrecht U., Atkins C., Sweatt J.D., Beaudet A.L. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998, 21:799-811. 10.1016/S0896-6273(00) 80,596-6.
86. Mabb A.M., Judson M.C., Zylka M.J., Philpot B.D. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 2011, 34:293-303. 10.1016/j.tins.2011.04.001. Angelman.
87. Jana N.R. Understanding the pathogenesis of Angelman syndrome through animal models. Neural Plast. 2012, 2012. 10.1155/2012/710943.
88. Miura K., Kishino T., Li E., Webber H., Dikkes P., Holmes G.L., et al. Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice. Neurobiol. Dis. 2002, 9:149-159. 10.1006/nbdi.2001.0463.
89. Dindot S., Antalffy B.A., Bhattacharjee M.B., Beaudet A.L. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum. Mol. Genet. 2008, 17:111-118. 10.1093/hmg/ddm288.
90. Yashiro K., Riday T.T., Condon K.H., Roberts A.C., Bernardo D.R., Prakash R., et al. Ube3a is required for experience-dependent maturation of the neocortex. Nat. Neurosci. 2009, 12:777-783. 10.1038/nn.2327.
91. Weeber E.J., Jiang Y.-H., Elgersma Y., Varga A.W., Carrasquillo Y., Brown S.E., et al. Derangements of hippocampal calcium/calmodulin-dependent protein kinase ii in a mouse model for Angelman mental retardation syndrome. J. Neurosci. 2003, 23:2634-2644. http://www.jneurosci.org/content/23/7/2634long.
92. van Woerden G.M., Harris K.D., Hojjati M.R., Gustin R.M., Qiu S., de Avila Freire R., et al. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat. Neurosci. 2007, 10:280-282. 10.1038/nn1845.
93. Pignatelli M., Piccinin S., Molinaro G., Di Menna L., Riozzi B., Cannella M., et al. Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling Angelman syndrome. J. Neurosci. 2014, 34:4558-4566. 10.1523/JNEUROSCI.1846-13.2014.
94. Jay V., Becker L.E., Chan F.-W., Perry T.L. Puppet-like syndrome of Angelman: a pathologic and neurochemical study. Neurology 1991, 41:416. 10.1212/WNL.41.3.416.
95. Sato M., Stryker M.P. Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5611-5616. 10.1073/pnas.1001281107.
96. Greer P.L., Hanayama R., Bloodgood B.L., Mardinly A.R., Lipton D.M., Flavell S.W., et al. The Angelman syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 2010, 140:704-716. 10.1016/j.cell.2010.01.026.
97. Shepherd J.D., Bear M.F. New views of Arc, a master regulator of synaptic plasticity. Nat. Neurosci. 2011, 14:279-284. 10.1038/nn.2708.
98. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y.S., Mele A., Fraser C.E., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261. 10.1016/j.cell.2011.06.013.
99. Neul J.L., Zoghbi H.Y. Rett syndrome: a prototypical neurodevelopmental disorder. Neuroscientist 2004, 10:118-128. 10.1177/1073858403260995.
100. Chapleau C., Larimore J.L., Theibert A., Pozzo-Miller L. Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. J. Neurodev. Disord. 2009, 1:185-196. 10.1007/s11689-009-9027-6.
101. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437. 10.1016/j.neuron.2007.10.001.
102. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188. 10.1038/13810.
103. Percy A.K., Lane J.B. Rett syndrome: clinical and molecular update. Curr. Opin. Pediatr. 2004, 16:670-677. http://www.ncbi.nlm.nih.gov/pubmed/15548931.
104. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T.C., Qin J., et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229. 10.1126/science.1153252.
105. Bauman M.L., Kemper T.L., Arin D.M. Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. Neurology 1995, 45:1581-1586.
106. Bauman M.L., Kemper T.L., Arin D.M. Microscopic observations of the brain in Rett syndrome. Neuropediatrics 1995, 26:105-108. 10.1055/s-2007-979737.
107. Armstrong D., Dunn J.K., Antalffy B., Trivedi R. Selective dendritic alterations in the cortex of Rett Syndrome. J. Neuropathol. Exp. Neurol. 1995, 54:195-201. http://journals.lww.com/jneuropath/Abstract/1995/03000/Selective_Dendritic_Alterations_in_the_Cortex_of.6aspx.
108. Kaufmann W.E., Taylor C., Hohmann C.F., Sanwal I.B., Naidu S. Abnormalities in neuronal maturation in Rett syndrome neocortex: preliminary molecular correlates. Eur. Child Adoles. Psy. 1997, 6(Suppl. 1):75-77. http://europepmc.org/abstract/MED/9452926.
109. Belichenko P.V., Oldfors A., Hagberg B., Dahlström A. Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 1994, 5:1509-1513. http://journals.lww.com/neuroreport/Abstract/1994/07000/Rett_syndrome__3_D_confocal_microscopy_of_cortical.25aspx.
110. Chapleau C., Calfa G.D., Lane M.C., Albertson A.J., Larimore J.L., Kudo S., et al. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol. Dis. 2009, 35:219-233. 10.1016/j.nbd.2009.05.001.
111. W. Li, L. Pozzo-Miller, Beyond Widespread Mecp2 Deletions to Model Rett Syndrome: Conditional Spatio-Temporal Knockout, Single-Point Mutations and Transgenic Rescue Mice, Autism Open Access. 2012 (2012) 1-20. doi:. Beyond. http://10.4172/2165-7890S1-005.
112. Xu X., Miller E.C., Pozzo-Miller L. Dendritic spine dysgenesis in Rett syndrome. Front. Neuroanat. 2014, 8:1-8. 10.3389/fnana.2014.00097.
113. Moretti P., Levenson J.M., Battaglia F., Atkinson R., Teague R., Antalffy B., et al. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J. Neurosci. 2006, 26:319-327. 10.1523/JNEUROSCI 2623-05.2006.
114. Asaka Y., Jugloff D.G.M., Zhang L., Eubanks J.H., Fitzsimonds R.M. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol. Dis. 2006, 21:217-227. 10.1016/j.nbd.2005.07.005.
115. Fukuda T., Itoh M., Ichikawa T., Washiyama K., Goto Y. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J. Neuropathol. Exp. Neurol. 2005, 64:537-544. http://www.ncbi.nlm.nih.gov/pubmed/15977646.
116. Nguyen F., Du C.A., Felice X., Shan A., et al. MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J. Neurosci. 2012, 32:10021-10034. 10.1523/JNEUROSCI.1316-12.2012.
117. Tropea D., Giacometti E., Wilson N.R., Beard C., McCurry C., Fu D.D., et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2029-2034. 10.1073/pnas.0812394106.
118. Chapleau C., Boggio E.M., Calfa G., Percy A.K., Giustetto M., Pozzo-Miller L. Hippocampal CA1 pyramidal neurons of Mecp2 mutant mice show a dendritic spine phenotype only in the presymptomatic stage. Neural Plast. 2012, 976:164. 10.1155/2012/976164.
119. Landi S., Putignano E., Boggio E.M., Giustetto M., Pizzorusso T., Ratto G.M. The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. Sci. Rep. 2011, 1:45. 10.1038/srep00045.
120. Castro J., Garcia R.I., Kwok S., Banerjee A., Petravicz J., Woodson J., et al. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:9941-9946. 10.1073/pnas.1311685111.
121. Chao H.-T., Zoghbi H.Y., Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 2007, 56:58-65. 10.1016/j.neuron.2007.08.018.
122. Baj G., Patrizio A., Montalbano A., Sciancalepore M., Tongiorgi E. Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro. Front. Cell Neurosci. 2014, 8:18. 10.3389/fncel.2014.00018.
123. Calfa G., Percy A.K., Pozzo-Miller L. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp. Biol. Med. (Maywood) 2011, 236:3-19. 10.1258/ebm.2010.010261.
124. Blackman M.P., Djukic B., Nelson S.B., Turrigiano G.G. A critical and cell-autonomous role for MeCP2 in synaptic scaling up. J. Neurosci. 2012, 32:13529-13536. 10.1523/JNEUROSCI 3077-12.2012.
125. Qiu Z., Sylwestrak E.L., Lieberman D.N., Zhang Y., Liu X.-Y., Ghosh A. The Rett syndrome protein MeCP2 regulates synaptic scaling. J. Neurosci. 2012, 32:989-994. 10.1038/35049004.
126. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32. 10.1038/35049004.
127. Ohira K., Hayashi M. A new aspect of the TrkB signaling pathway in neural plasticity. Curr. Neuropharmacol. 2009, 7:276-285. 10.2174/157015909790031210.
128. Chapleau C., Pozzo-Miller L. Divergent roles of p75NTR and Trk receptors in BDNF's effects on dendritic spine density and morphology. Neural Plast. 2012, 2012:578057. 10.1155/2012/578057.
129. D. Panja, C.R. Bramham, BDNF mechanisms in late LTP formation: A synthesis and breakdown., Neuropharmacology. 76 Pt C (2014) 664-76. doi:. http://10.1016/j.neuropharm.2013.06.024.
130. Chang Q., Khare G., Dani V., Nelson S., Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006, 49:341-348. 10.1016/j.neuron.2005.12.027.
131. Wang H., Chan S., Ogier M., Hellard D., Wang Q., Smith C., et al. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J. Neurosci. 2006, 26. 10911-10915. 10.1523/JNEUROSCI 1810-06.2006.
132. Li W., Calfa G., Larimore J., Pozzo-Miller L. Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17087-17092. 10.1073/pnas.1205271109.
133. Zhong X., Li H., Chang Q. MeCP2 phosphorylation is required for modulating synaptic scaling through mGluR5. J. Neurosci. 2012, 32:12841-12847. 10.1523/JNEUROSCI 2784-12.2012.
134. Willemsen R., Levenga J., Oostra B.A. CGG repeat in the FMR1 gene: size matters. Clin. Genet. 2011, 80:214-225. 10.1111/j. 1399-0004.2011.01723. x.
135. Sabaratnam M., Vroegop P.G., Gangadharan S.K. Epilepsy and EEG findings in 18 males with fragile X syndrome. Seizure 2001, 10:60-63. 10.1053/seiz.2000.0492.
136. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev. Med. Child Neurol. 2007, 44:724-728. 10.1111/j. 1469-8749.2002.tb00277.x.
137. Hagerman R., Berry-Kravis E., Kaufmann W.E., Ono M.Y., Tartaglia N., Lachiewicz A. Advances in the treatment of fragile X syndrome. Pediatrics 2009, 123:378-390. 10.1542/peds 2008-0317.
138. Hagerman P., Stafstrom C.E. Origins of epilepsy in fragile X syndrome. Epilepsy Curr. 2009, 9:108-112. 10.1111/j 1535-7511.2009.01309.x.
139. Santoro M.R., Bray S.M., Warren S.T. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 2012, 7:219-245. 10.1146/annurev-pathol-011811-132457.
140. Rudelli R.D., Brown W.T., Wisniewski K., Jenkins E.C., Laure-Kamionowska M., Connell F. Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol. 1985, 67:289-295. http://www.ncbi.nlm.nih.gov/pubmed/4050344.
141. Hinton V.J., Brown W.T., Wisniewski K., Rudelli R.D. Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet. 1991, 41:289-294. 10.1002/ajmg.1320410306.
142. Irwin S.A., Patel B., Idupulapati M., Harris J.B., Crisostomo R.A., Larsen B.P. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet. 2001, 98:161-167. http://www.ncbi.nlm.nih.gov/pubmed/11223852.
143. Irwin S.A., Idupulapati M., Gilbert M.E., Harris J.B., Chakravarti A.B., Rogers E.J., et al. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am. J. Med. Genet. 2002, 111:140-146. 10.1002/ajmg.10500.
144. Comery T.A., Harris J.B., Willems P.J., Oostra B.A., Irwin S.A., Weiler I.J., et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad. Sci. 1997, 94:5401-5404. 10.1073/pnas.94.10.5401.
145. Galvez R., Greenough W.T. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am. J. Med. Genet. A 2005, 135:155-160. 10.1002/ajmg.a.30709.
146. McKinney B.C., Grossman A.W., Elisseou N.M., Greenough W.T. Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2005, 136B:98-102. 10.1002/ajmg.b.30183.
147. Portera-Cailliau C. Which comes first in fragile X syndrome, dendritic spine dysgenesis or defects in circuit plasticity?. Neuroscientist 2012, 18:28-44. 10.1177/1073858410395322.
148. Nimchinsky E.A., Oberlander A.M., Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. J. Neurosci. 2001, 21:5139-5146. http://www.jneurosci.org/content/21/14/5139abstract.
149. Meredith R.M., Holmgren C.D., Weidum M., Burnashev N., Mansvelder H.D. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. Neuron 2007, 54:627-638. 10.1016/j.neuron.2007.04.028.
150. Cruz-Martín A., Crespo M., Portera-Cailliau C. Delayed stabilization of dendritic spines in fragile X mice. J. Neurosci. 2010, 30:7793-7803. 10.1523/JNEUROSCI 0577-10.2010.
151. Koekkoek S.K.E., Yamaguchi K., Milojkovic B.A., Dortland B.R., Ruigrok T.J.H., Maex R. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron 2005, 47:339-352. 10.1016/j.neuron.2005.07.005.
152. Restivo L., Ferrari F., Passino E., Sgobio C., Bock J., Oostra B.A., et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11557-11562. 10.1073/pnas.0504984102.
153. Antar L.N., Li C., Zhang H., Carroll R.C., Bassell G.J. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol. Cell. Neurosci. 2006, 32:37-48. 10.1016/j.mcn.2006.02.001.
154. Bilousova T.V., Dansie L., Ngo M., Aye J., Charles J.R., Ethell D.W., et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 2009, 46:94-102. 10.1136/jmg.2008.061796.
155. Pop A.S., Levenga J., de Esch C.E.F., Buijsen R.A.M., Nieuwenhuizen I.M., Li T. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology 2014, 231:1227-1235. 10.1007/s00213-012-2947-y.
156. Pan F., Aldridge G.M., Greenough W.T., Gan W.-B. Dendritic spine instability and insensitivity to modulation by sensory experience in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17768-17773. 10.1073/pnas.1012496107.
157. Li J., Pelletier M.R., Perez Velazquez J.-L., Carlen P.L. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol. Cell. Neurosci. 2002, 19:138-151. 10.1006/mcne.2001.1085.
158. Zhao M.-G., Toyoda H., Ko S.W., Ding H.-K., Wu L.-J., Zhuo M. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J. Neurosci. 2005, 25:7385-7392. 10.1523/JNEUROSCI 1520-05.2005.
159. Desai N.S., Casimiro T.M., Gruber S.M., Vanderklish P.W. Early postnatal plasticity in neocortex of Fmr1 knockout mice. J. Neurophysiol. 2006, 96:1734-1745. 10.1152/jn.00221.2006.
160. Wilson B.M., Cox C.L. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2454-2459. 10.1073/pnas.0610875104.
161. Godfraind J.M., Reyniers E., De Boulle K., D'Hooge R., De Deyn P.P., Bakker C.E., et al. Long-term potentiation in the hippocampus of fragile X knockout mice. Am. J. Med. Genet. 1996, 64:246-251. 10.1002/(SICI) 1096-8628(19,960,809)64:2<246::AID-AJMG2>3.0.CO;2-S.
162. Paradee W., Melikian H.E., Rasmussen D.L., Kenneson A., Conn P.J., Warren S.T. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 1999, 94:185-192. 10.1016/S0306-4522(99) 285-7.
163. Larson J., Jessen R.E., Kim D., Fine A.-K.S., du Hoffmann J. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J. Neurosci. 2005, 25:9460-9469. 10.1523/JNEUROSCI 2638-05.2005.
164. Lauterborn J.C., Rex C.S., Kramár E., Chen L.Y., Pandyarajan V., Lynch G., et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J. Neurosci. 2007, 27:10685-10694. 10.1523/JNEUROSCI.2624-07.2007.
165. Hu H., Qin Y., Bochorishvili G., Zhu Y., van Aelst J.J. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J. Neurosci. 2008, 2(8). 7847-7862. 10.1073/pnas.1012496107.
166. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7746-7750. 10.1073/pnas.122205699.
167. Hou L., Antion M.D., Hu D., Spencer C.M., Paylor R., Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 2006, 51:441-454. 10.1016/j.neuron.2006.07.005.
168. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377. 10.1016/j.tins.2004.04.009.
169. Dölen G., Bear M.F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J. Physiol. 2008, 586:1503-1508. 10.1113/jphysiol.2008.150722.
170. Osborne J.P., Fryer A., Webb D. Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 1991, 615:125-127. http://www.ncbi.nlm.nih.gov/pubmed/2039137.
171. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372. 657-668. 10.1016/S0140-6736(08)61,279-9.
172. Gutierrez G.C., Smalley S.L., Tanguay P.E. Autism in tuberous sclerosis complex. J. Autism Dev. Disord. 1998, 28:97-103. http://www.ncbi.nlm.nih.gov/pubmed/9586771.
173. Curatolo P., Napolioni V., Moavero R. Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment. J. Child Neurol. 2010, 25:873-880. 10.1177/0883073810361789.
174. Hunt A., Dennis J. Psychiatric disorder among children with tuberous sclerosis. Dev. Med. Child Neurol. 2008, 29:190-198. 10.1111/j.1469-8749.1987.tb02135.x.
175. van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808. http://www.ncbi.nlm.nih.gov/pubmed/9242607.
176. Kandt R.S., Haines J.L., Smith M., Northrup H., Gardner R.J., Short M.P., et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat. Genet. 1992, 2:37-41. 10.1038/ng0992-37.
177. van Slegtenhorst M., Nellist M., Nagelkerken B., Cheadle J., Snell R., van den Ouweland A. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 1998, 7:1053-1057. http://www.ncbi.nlm.nih.gov/pubmed/9580671.
178. Inoki K., Li Y., Xu T., Guan K.-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17:1829-1834. 10.1101/gad.1110003.
179. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., et al. Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2. Mol. Cell 2003, 11:1457-1466. 10.1016/S1097-2765(03) 220-X.
180. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., Blenis J. Tuberous sclerosis complex gene products, tuberin and hamartin, control mtor signaling by acting as a gtpase-activating protein complex toward rheb. Curr. Biol. 2003, 13. 10.1016/S0960-9822(03)00506-2.
181. Manning B.D., Cantley L.C. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 2003, 28:573-576. 10.1016/j.tibs.2003.09.003.
182. a Guertin D., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22. 10.1016/j.ccr.2007.05.008.
183. Tavazoie S.F., a Alvarez V., a Ridenour D., Kwiatkowski D.J., Sabatini B.L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 2005, 8:1727-1734. 10.1038/nn1566.
184. Jaworski J., Sheng M. The growing role of mTOR in neuronal development and plasticity. Mol. Neurobiol. 2006, 34:205-219. 10.1385/MN:34:3:205.
185. de Vries P.J., Howe C.J. The tuberous sclerosis complex proteins - a GRIPP on cognition and neurodevelopment. Trends Mol. Med. 2007, 13:319-326. 10.1016/j.molmed.2007.06.003.
186. Swiech L., Perycz M., Malik A., Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochim. Biophys. Acta 2008, 1784:116-132. 10.1016/j.bbapap.2007.08.015.
187. Richter J.D., Klann E. Making synaptic plasticity and memory last: mechanisms of translational regulation. Genes Dev. 2009, 23:1-11. 10.1101/gad.1735809.
188. Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann. N. Y. Acad. Sci. 2010, 1184:87-105. 10.1111/j.1749-6632.2009.05117.x.
189. Zeng L.-H., Ouyang Y., Gazit V., Cirrito J.R., Jansen L.A., Ess K.C., et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 2007, 28:184-196. 10.1016/j.nbd.2007.07.015.
190. Ehninger D., Han S., Shilyansky C., Zhou Y., Li W., Kwiatkowski D.J., et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 2008, 14:843-848. 10.1038/nm1788.
191. Auerbach B.D., Bear M.F. Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. J. Neurophysiol. 2010, 104:1047-1051. 10.1152/jn.00449.2010.
192. Bateup H.S., Takasaki K.T., Saulnier J.L., Denefrio C.L., Sabatini B.L. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J. Neurosci. 2011, 31:8862-8869. 10.1523/JNEUROSCI.1617-11.2011.
193. Chévere-Torres I., Kaphzan H., Bhattacharya A., Kang A., Maki J.M., Gambello M.J., et al. Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the (RG mouse model of tuberous sclerosis complex. Neurobiol. Dis. 2012, 45:1101-1110. 10.1016/j.nbd.2011.12.028.
194. Kirschstein T. Synaptic plasticity and learning in animal models of tuberous sclerosis complex. Neural Plast. 2012, 2012:279834. 10.1155/2012/279834.
195. Goorden S.M.I., van Woerden G.M., van der Weerd L., Cheadle J.P., Elgersma Y. Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann. Neurol. 2007, 62:648-655. 10.1002/ana.21317.
196. Auerbach B.D., Osterweil E.K., Bear M.F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011, 480:63-68. 10.1038/nature10658.
197. Ehninger D., Silva A.J. Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis. Behav. Genet. 2011, 41:357-363. 10.1007/s10519-010-9398-1.Increased.
198. Chévere-Torres I., Maki J.M., Santini E., Klann E. Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin. Neurobiol. Dis. 2012, 45:156-164. 10.1016/j.nbd.2011.07.018.
199. Yasuda S., Sugiura H., Katsurabayashi S., Shimada T., Tanaka H., Takasaki K. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex. Sci. Rep. 2014, 4:51-55. 10.1038/srep05155.
200. Tang G., Gudsnuk K., Kuo S.-H., Cotrina M.L., Rosoklija G., Sosunov A., et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 2014, 113:1-1143. 10.1016/j.neuron.2014.07.040.
201. Zuo Y., Yang G., Kwon E., Gan W.-B. Long-term sensory deprivation prevents dendritic spine loss in primary somatosensory cortex. Nature 2005, 436:261-265. 10.1038/nature03715.
202. Kelleher R.J., Bear M.F. The autistic neuron: troubled translation?. Cell 2008, 135:401-406. 10.1016/j.cell.2008.10.017.
203. Troca-Marín J.A., Alves-Sampaio A., Montesinos M.L. Deregulated mTOR-mediated translation in intellectual disability. Prog. Neurobiol. 2012, 96:268-282. 10.1016/j.pneurobio.2012.01.005.
204. Costa-Mattioli M., Monteggia L.M. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat. Neurosci. 2013, 16:1537-1543. 10.1038/nn.3546.
205. Bowling H., Klann E. Shaping dendritic spines in autism spectrum disorder: mTORC1-dependent macroautophagy. Neuron 2014, 83:994-996. 10.1016/j.neuron.2014.08.021.
206. Zalfa F., Giorgi M., Primerano B., Moro A., Di Penta A., Reis S., et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003, 112:317-327. http://www.ncbi.nlm.nih.gov/pubmed/12581522.
207. Bateup H.S., a Johnson C., Denefrio C.L., Saulnier J.L., Kornacker K., Sabatini B.L. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 2013, 78:510-522. 10.1016/j.neuron.2013.03.017.
208. Ogier M., Wang H., Hong E., Wang Q., Greenberg M.E., Katz D.M. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J. Neurosci. 2007, 27:10912-10917. 10.1523/JNEUROSCI.1869-07.2007.
209. Xu X., Kozikowski A.P., Pozzo-Miller L. A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. Front. Cell. Neurosci. 2014, 8:1-9. 10.3389/fncel.2014.00068.
210. Alonso M., Medina J.H., Pozzo-Miller L. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn. Memory 2015, 11:172-178. (n.d.). 10.1101/lm.67804.
211. Kumar V., Zhang M.-X., Swank M.W., Kunz J., Wu G.-Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 2005, 25:11288-11299. 10.1523/JNEUROSCI.2284-05.2005.
212. Ricciardi S., Boggio E.M., Grosso S., Lonetti G., Forlani G., Stefanelli G., et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Genet. 2011, 20:1182-1196. 10.1093/hmg/ddq563.
213. Herman G.E., Butter E., Enrile B., Pastore M., Prior T.W., Sommer A. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am. J. Med. Genet. A 2007, 143A:589-593. 10.1002/ajmg.a.31619.
214. Orrico A., Galli L., Buoni S., Orsi A., Vonella G., Sorrentino V. Novel PTEN mutations in neurodevelopmental disorders and macrocephaly. Clin. Genet. 2009, 75:195-198. 10.1111/j. 1399-0004.2008.01074. x.
215. Varga E.A., Pastore M., Prior T., Herman G.E., McBride K.L. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet. Med. 2009, 11:111-117. 10.1097/GIM.0b013e31818fd762.
216. McBride K.L., Varga E.A., Pastore M.T., Prior T.W., Manickam K., Atkin J.F., et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res. 2010, 3:137-141. 10.1002/aur.132.
217. O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012, 338:1619-1622. 10.1126/science.1227764.
218. Hobert J.A., Embacher R., Mester J.L., Frazier T.W., Eng C. Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. Eur. J. Hum. Genet. 2014, 22:273-276. 10.1038/ejhg.2013.114.
219. Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., Takahashi T.N., et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 2005, 42:318-321. 10.1136/jmg.2004.024646.
220. Kwon C.-H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388. 10.1016/j.neuron.2006.03.023.
221. Zoghbi H.Y., Bear M.F. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 2012, 4. 10.1101/cshperspect.a009886.
222. Troca-Marín J.A., Alves-Sampaio A., Montesinos M.L. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome. J. Neurosci. 2011, 31:9445-9455. 10.1523/JNEUROSCI.0011-11.2011.
223. Iyer A.M., van Scheppingen J., Milenkovic I., Anink J.J., Adle-Biassette H., Kovacs G.G., et al. mTOR Hyperactivation in Down syndrome hippocampus appears early during development. J. Neuropathol. Exp. Neurol. 2014, 73.
224. Bastrikova, Gardner G.A., Reece J.M., Jeromin A., Dudek S.M. Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3123-3127. 10.1073/pnas.0800027105.
225. Shinoda Y., Tanaka T., Tominaga-Yoshino K., Ogura A. Persistent synapse loss induced by repetitive LTD in developing rat hippocampal neurons. PLoS One 2010, 5:e10390. 10.1371/journal.pone.0010390.
226. Watanabe M., Kano M. Climbing fiber synapse elimination in cerebellar Purkinje cells. Eur. J. Neurosci. 2011, 34:1697-1710. 10.1111/j. 1460-9568.2011.07894.x.
227. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 2008, 28:5422-5432. 10.1523/JNEUROSCI.0955-08.2008.
228. Cambiaghi M., Cursi M., Magri L., Castoldi V., Comi G., Minicucci F. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology 2013, 67:1-7. 10.1016/j.neuropharm.2012.11.003.
229. S. Ramón y Cajal, Textura Del Sistema Nervioso Del Hombre Y De Los Vertebrados, Moya, Madrid, 1904. http://www.casadellibro.com/libro-textura-del-sistema-nervioso-del-hombre-y-de-los-vertebrados-3-v-ols/9788477539254/845754.
230. Ehninger D., Li W., Fox K., Stryker M.P., Silva A.J. Reversing neurodevelopmental disorders in adults. Neuron 2008, 60:950-960. 10.1016/j.neuron.2008.12.007.
231. Guy J., Gan J., Selfridge J., Cobb S., Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147. 10.1126/science.1138389.
232. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413. 10.1038/nn1860.
233. Rueda N., Flórez J., Martínez-Cué C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 2008, 433:22-27. 10.1016/j.neulet.2007.12.039.